Format

Send to

Choose Destination
BMC Clin Pharmacol. 2009 Oct 23;9:16. doi: 10.1186/1472-6904-9-16.

Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.

Author information

1
Division of Basic Medical Sciences, Southwest College of Naturopathic Medicine, Tempe, AZ, USA. jim.adams@asu.edu

Abstract

BACKGROUND:

This study investigated the effect of oral dimercapto succinic acid (DMSA) therapy for children with autism spectrum disorders ages 3-8 years.

METHODS:

Phase 1 involved 65 children who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.

RESULTS:

DMSA greatly increased the excretion of lead, substantially increased excretion of tin and bismuth, and somewhat increased the excretion of thallium, mercury, antimony, and tungsten. There was some increase in urinary excretion of essential minerals, especially potassium and chromium. The Phase 1 single round of DMSA led to a dramatic normalization of RBC glutathione in almost all cases, and greatly improved abnormal platelet counts, suggesting a significant decrease in inflammation.

CONCLUSION:

Overall, DMSA therapy seems to be reasonably safe, effective in removing several toxic metals (especially lead), dramatically effective in normalizing RBC glutathione, and effective in normalizing platelet counts. Only 1 round (3 days) was sufficient to improve glutathione and platelets. Additional rounds increased excretion of toxic metals.

PMID:
19852789
PMCID:
PMC2774660
DOI:
10.1186/1472-6904-9-16
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center